Infinity Pharmaceuticals Inc.

0.5373+0.0173+3.33%Vol 1.06M1Y Perf -80.45%
May 13th, 2022 16:00 DELAYED
BID0.5200 ASK0.5600
Open0.5250 Previous Close0.5200
Pre-Market- After-Market0.56
 - -  0.02 4.22%
Target Price
6.80 
Analyst Rating
Strong Buy 1.00
Potential %
1.17K 
Finscreener Ranking
★★     45.04
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     38.66
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
     34.70
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
2.24 
Earnings Rating
Strong Buy
Market Cap47.90M 
Earnings Date
3rd May 2022
Alpha-0.01 Standard Deviation0.27
Beta2.16 

Today's Price Range

0.52120.5962

52W Range

0.46053.89

5 Year PE Ratio Range

-3.90-3.50

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-24.25%
1 Month
-40.03%
3 Months
-52.45%
6 Months
-78.68%
1 Year
-80.45%
3 Years
-62.43%
5 Years
-68.58%
10 Years
-96.04%

TickerPriceChg.Chg.%
INFI0.53730.01733.33
AAPL147.114.55003.19
GOOG2 330.3167.09002.96
MSFT261.125.77002.26
XOM88.862.56002.97
WFC42.640.83001.99
JNJ176.85-1.0200-0.57
FB198.627.38003.86
GE75.051.77002.42
JPM119.091.05000.89
Financial StrengthValueIndustryS&P 500US Markets
6.10
6.20
0.70
2.37
-250.50
Leverage Ratio 3.00
ProfitabilityValueIndustryS&P 500US Markets
39.70
-2 426.40
-2 400.50
-1 448.80
-
RevenueValueIndustryS&P 500US Markets
1.39M
0.02
-56.33
-32.72
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.14-0.140.00
Q04 2021-0.14-0.137.14
Q03 2021-0.14-0.1214.29
Q02 2021-0.13-0.130.00
Q01 2021-0.14-0.15-7.14
Q04 2020-0.16-0.17-6.25
Q03 2020-0.15-0.16-6.67
Q02 2020-0.20-0.1620.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.1417.65Positive
9/2022 QR-0.1041.18Positive
12/2022 FY-0.5514.06Positive
12/2023 FY-0.647.25Positive
Next Report Date-
Estimated EPS Next Report-0.14
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume1.06M
Shares Outstanding89.16K
Shares Float87.22M
Trades Count4.34K
Dollar Volume579.49K
Avg. Volume893.04K
Avg. Weekly Volume1.13M
Avg. Monthly Volume805.62K
Avg. Quarterly Volume741.11K

Infinity Pharmaceuticals Inc. (NASDAQ: INFI) stock closed at 0.5373 per share at the end of the most recent trading day (a 3.33% change compared to the prior day closing price) with a volume of 1.06M shares and market capitalization of 47.90M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 25 people. Infinity Pharmaceuticals Inc. CEO is Adelene Q. Perkins.

The one-year performance of Infinity Pharmaceuticals Inc. stock is -80.45%, while year-to-date (YTD) performance is -76.12%. INFI stock has a five-year performance of -68.58%. Its 52-week range is between 0.4605 and 3.89, which gives INFI stock a 52-week price range ratio of 2.24%

Infinity Pharmaceuticals Inc. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 2.93, a price-to-sale (PS) ratio of 45.51, a price to cashflow ratio of 8.50, a PEG ratio of 2.32, a ROA of -74.57%, a ROC of -71.48% and a ROE of -53 106.80%. The company’s profit margin is -%, its EBITDA margin is -2 400.50%, and its revenue ttm is $1.39 Million , which makes it $0.02 revenue per share.

Of the last four earnings reports from Infinity Pharmaceuticals Inc., there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.14 for the next earnings report. Infinity Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Infinity Pharmaceuticals Inc. is Strong Buy (1), with a target price of $6.8, which is +1 165.59% compared to the current price. The earnings rating for Infinity Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Infinity Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Infinity Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 18.57, ATR14 : 0.08, CCI20 : -163.39, Chaikin Money Flow : -0.20, MACD : -0.11, Money Flow Index : 18.81, ROC : -33.04, RSI : 26.95, STOCH (14,3) : 18.09, STOCH RSI : 0.43, UO : 32.04, Williams %R : -81.91), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Infinity Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
7 (100.00 %)
7 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Infinity Pharmaceuticals Inc.

Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments. The company operates in only one segment which is drug development.

CEO: Adelene Q. Perkins

Telephone: +1 617 453-1000

Address: 1100 Massachusetts Avenue, Cambridge 02138, MA, US

Number of employees: 25

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

65%35%

News

Stocktwits